National Institute on Drug Abuse; Notice of Closed Meetings, 47633-47634 [2018-20423]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 183 / Thursday, September 20, 2018 / Notices
Contact Person: Liliana Norma BertiMattera, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 4215, Bethesda, MD 20892,
liliana.berti-mattera@nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Community-Level Health Promotion Study
Section.
Date: October 15–16, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Westin Georgetown, 2350 M Street,
NW, Washington, DC 20037.
Contact Person: Ping Wu, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3166, Bethesda, MD 20892, 301–
451–8428 wup4@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–GM–
18–002: Training Modules to Enhance the
Rigor and Reproducibility of Biomedical
Research (R25).
Date: October 16, 2018.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Vonda K. Smith, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6188,
MSC 7892, Bethesda, MD 20892, 301–435–
1789, smithvo@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 14, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–20414 Filed 9–19–18; 8:45 am]
BILLING CODE 4140–01–P
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; State-ofthe-Art Functional MRI Approaches
Combined with MVPA (9916).
Date: October 4, 2018.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 827–5702, lf33c.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Assessment of Potential Substance Abuse
Treatment Medications in Nonhuman
Primate Models (8946).
Date: October 18, 2018.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 827–5702, f33c.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
amozie on DSK3GDR082PROD with NOTICES1
[FR Doc. 2018–20422 Filed 9–19–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute on Drug Abuse;
Notice of Closed Meetings
National Institutes of Health
Jkt 244001
Dated: September 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–20417 Filed 9–19–18; 8:45 am]
National Institutes of Health
18:01 Sep 19, 2018
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
Research Committee.
Date: October 18–19, 2018.
Time: 8:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Amir E. Zeituni, Ph.D.,
Scientific Review Program, Division of
Extramural Activities, SRP, RM 3G51
National Institutes of Health, NIAID, 5601
Fishers Lane, MSC 9823, Rockville, MD
20852–9823, 301–496–2550, amir.zeituni@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Dated: September 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
47633
National Institute of Allergy and
Infectious Diseases Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting Microbiology, Infectious
Diseases and AIDS Initial Review Group
Microbiology and Infectious Diseases
Research Committee.
The meeting will be closed to the
public in accordance with the
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
National Institute on Drug Abuse;
Notice of Closed Meetings
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploiting Omics Assays to Investigate
Molecular Regulation of Persistent HIV in
E:\FR\FM\20SEN1.SGM
20SEN1
amozie on DSK3GDR082PROD with NOTICES1
47634
Federal Register / Vol. 83, No. 183 / Thursday, September 20, 2018 / Notices
Individuals with Substance Use Disorder
(R61/R33 Clinical Trial Optional).
Date: October 3, 2018.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 9550, Bethesda,
MD 20892, 301–827–5842, ramadanir@
mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploring Epigenomic or Non-Coding RNA
Regulation in the Development,
Maintenance, or Treatment of Chronic Pain
(R61/R33 Clinical Trial Optional).
Date: October 12, 2018.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 9550, Bethesda,
MD 20892, 301–827–5842, ramadanir@
mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Coordinating Center to Support NIDA Rural
Opioid HIV and Comorbidity Initiative
(U24—Clinical Trial Not Allowed).
Date: October 17, 2018.
Time: 2:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
AGENCY:
[FR Doc. 2018–20423 Filed 9–19–18; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:01 Sep 19, 2018
Jkt 244001
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Institutional
Training Grants.
Date: October 17, 2018.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Kimberly Firth, Ph.D.,
National Institutes of Health, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7702, firthkm@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: September 14, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–20420 Filed 9–19–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of New NIH Policy Manual
1311—Preventing and Addressing
Harassment and Inappropriate
Conduct and New Policy Statement on
Inappropriate Relationships in the
Workplace
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institutes of
Health (NIH) announces Policy Manual
Chapter: 1311—Preventing and
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Addressing Harassment and
Inappropriate Conduct and a new Policy
Statement addressing Personal
Relationships in the Workplace. These
policies apply to federal employees,
contractors, trainees, and fellows who
perform work for the NIH. The NIH
expects that organizations receiving NIH
funds have in place similarly rigorous
policies and related procedures for their
employees, contractors, trainees, and
fellows who engage in agency-funded
activities.
FOR FURTHER INFORMATION CONTACT: For
further information about these new
policies, contact Jessica Hawkins, Office
of Human Resources, National Institutes
of Health, Building 31, Room 1/B37,
Bethesda, Maryland 20892, telephone
301–402–8006 (not a toll-free number),
hawkinj@od.nih.gov.
SUPPLEMENTARY INFORMATION: Policy
Manual 1311—Preventing and
Addressing Harassment and
Inappropriate Conduct states that the
NIH will not tolerate inappropriate
conduct or harassment, including sexual
harassment. Timely and appropriate
action will be taken against any
individual found to be in violation of
the policy outlined in the Manual
Chapter. Through enforcement of this
policy, the NIH seeks to prevent,
correct, and eliminate unacceptable
behavior that is inconsistent with the
values and culture of respect and
inclusion. Further, the policy is
intended to increase the transparency
and consistency in how allegations of
harassment are reviewed and resolved.
NIH leadership has designated the
Office of Human Resources’ Civil
Program as the entity charged with
receiving allegations of harassment and
overseeing relevant administrative
inquiries.
The NIH Policy Statement on Personal
Relationships in the Workplace states
that personal relationships (including
romantic and/or sexual) between
individuals in inherently unequal
positions, where one party has real or
perceived authority over the other in
their professional roles, may be
inappropriate in the workplace and are
strongly discouraged. If such a
relationship exists or develops, it must
be disclosed. Upon such notification,
the responsible agency official must
insure that the NIH Institute/Center
manages, decreases, or eliminates
potential risk as a result of the
relationship.
This applies to all individuals in the
NIH community, including employees,
contractors, students, trainees, and
fellows and includes anyone who holds
a position of authority or perceived
E:\FR\FM\20SEN1.SGM
20SEN1
]]>Agencies
[Federal Register Volume 83, Number 183 (Thursday, September 20, 2018)]
[Notices]
[Pages 47633-47634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20423]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploiting Omics Assays to Investigate Molecular
Regulation of Persistent HIV in
[[Page 47634]]
Individuals with Substance Use Disorder (R61/R33 Clinical Trial
Optional).
Date: October 3, 2018.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892,
301-827-5842, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploring Epigenomic or Non-Coding RNA Regulation in
the Development, Maintenance, or Treatment of Chronic Pain (R61/R33
Clinical Trial Optional).
Date: October 12, 2018.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892,
301-827-5842, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Coordinating Center to Support NIDA Rural Opioid HIV
and Comorbidity Initiative (U24--Clinical Trial Not Allowed).
Date: October 17, 2018.
Time: 2:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: September 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-20423 Filed 9-19-18; 8:45 am]
BILLING CODE 4140-01-P
